Despite significant investment and a fourfold increase in use, traditional CGM systems are not moving the A1C needle. A recent report from the T1D Exchange shows only 21.5% of Type 1 adults are meeting the ADA A1C goal of 7.0%, and glycemic control has not improved overall since their report of data from 2010-2012.


Offer a unique implantable alternative to traditional CGM that overcomes common barriers hindering better patient control.